Template:Pharmacomodulation: Difference between revisions
Content deleted Content added
m page name change |
m Disambiguating links to Serotonergic (link changed to Serotonin) using DisamAssist. |
||
| (24 intermediate revisions by 11 users not shown) | |||
| Line 1: | Line 1: | ||
{{Navbox |
{{Navbox |
||
| name = Pharmacomodulation |
|||
| title = [[Pharmacology|Pharmacomodulation]] |
|||
| name = Neuromodulation |
|||
| state = {{{state<includeonly>|collapsed</includeonly>}}} |
|||
| title = [[Neuromodulation]] |
|||
| ⚫ | |||
| state = {{{state|autocollapse}}} |
|||
| ⚫ | |||
| group1 = Types |
| group1 = Types |
||
| list1 = |
| list1 = |
||
* ♦ [[Enzyme]]: [[Enzyme inducer|Inducer]] |
* ♦ [[Enzyme]]: [[Enzyme inducer|Inducer]] |
||
* [[Enzyme inhibitor|Inhibitor]] |
* [[Enzyme inhibitor|Inhibitor]] |
||
| Line 15: | Line 14: | ||
* ♦ [[Receptor (biochemistry)|Receptor]]: [[Agonist]] |
* ♦ [[Receptor (biochemistry)|Receptor]]: [[Agonist]] |
||
| ⚫ | |||
* [[Receptor antagonist|Antagonist]] |
* [[Receptor antagonist|Antagonist]] |
||
* [[Inverse agonist]] |
|||
* [[Positive allosteric modulator]] (PAM) |
* [[Positive allosteric modulator]] (PAM) |
||
* [[Negative allosteric modulator]] (NAM) |
* [[Negative allosteric modulator]] (NAM) |
||
| ⚫ | |||
* ♦ [[Membrane transport protein|Transporter]] <nowiki>[</nowiki>[[Reuptake]]<nowiki>]</nowiki>: [[Reuptake enhancer|Enhancer]] (RE) |
* ♦ [[Membrane transport protein|Transporter]] <nowiki>[</nowiki>[[Reuptake]] vs [[Reverse transport|Efflux]]<nowiki>]</nowiki>: [[Reuptake enhancer|Enhancer]] (RE) |
||
* [[Reuptake inhibitor|Inhibitor]] (RI) |
* [[Reuptake inhibitor|Inhibitor]] (RI) |
||
* [[Releasing agent|Releaser]] (RA) |
* [[Releasing agent|Releaser]] (RA) |
||
| Line 28: | Line 28: | ||
| group2 = Classes |
| group2 = Classes |
||
| list2 = {{Navbox |
| list2 = {{Navbox|subgroup |
||
| group1 = [[Enzyme]] |
| group1 = [[Enzyme]] |
||
| Line 35: | Line 35: | ||
| group2 = [[Ion channel]] |
| group2 = [[Ion channel]] |
||
| list2 = |
| list2 = |
||
See [[template:channel blockers|Ion channel modulators]] |
|||
* [[Potassium channel blocker]] (PCB) |
|||
* [[Sodium channel blocker]] (SCB) |
|||
* [[Potassium channel opener]] (PCO) |
|||
| group3 = [[Receptor (biochemistry)|Receptor]] &<br/>[[Membrane transport protein|transporter]] |
| group3 = [[Receptor (biochemistry)|Receptor]] &<br/>[[Membrane transport protein|transporter]] |
||
| list3 = {{Navbox |
| list3 = {{Navbox|subgroup |
||
| group1 = [[Biogenic amine|BA]]/[[Monoamine neurotransmitter|M]] |
| group1 = [[Biogenic amine|BA]]/[[Monoamine neurotransmitter|M]] |
||
| list1 = {{Navbox |
| list1 = {{Navbox|subgroup |
||
| group1 = [[Adrenergic]] |
| group1 = [[Adrenergic]] |
||
| Line 53: | Line 49: | ||
* [[Beta2-adrenergic agonist|2]])) |
* [[Beta2-adrenergic agonist|2]])) |
||
* [[Adrenergic antagonist|Adrenergic receptor antagonist]] ([[Alpha blocker|α]] ([[Alpha-1 blocker|1]] |
* [[Adrenergic antagonist|Adrenergic receptor antagonist]] ([[Alpha blocker|α]] ([[Alpha-1 blocker|1]] |
||
* [[Alpha-2 blocker|2]]) |
* [[Alpha-2 blocker|2]]) |
||
* [[Beta blocker|β]]) |
|||
* [[Norepinephrine |
* [[Norepinephrine reuptake inhibitor]] (NRI) |
||
| group3 = [[Dopaminergic]] |
| group3 = [[Dopaminergic]] |
||
| Line 62: | Line 59: | ||
* [[Dopamine reuptake inhibitor]] (DRI) |
* [[Dopamine reuptake inhibitor]] (DRI) |
||
| group5 = [[ |
| group5 = [[Histaminergic]] |
||
| list5 = |
| list5 = |
||
* [[Histamine agonist|Histamine receptor agonist]] |
* [[Histamine agonist|Histamine receptor agonist]] |
||
| Line 69: | Line 66: | ||
* [[H3 receptor antagonist|H<sub>3</sub>]]) |
* [[H3 receptor antagonist|H<sub>3</sub>]]) |
||
| group9 = [[Serotonergic]] |
| group9 = [[Serotonin|Serotonergic]] |
||
| list9 = |
| list9 = |
||
* [[Serotonin receptor agonist]] |
* [[Serotonin receptor agonist]] |
||
* [[Serotonin antagonist|Serotonin |
* [[Serotonin antagonist|Serotonin receptor antagonist]] ([[5-HT3 antagonist|5-HT<sub>3</sub>]]) |
||
* [[Serotonin reuptake inhibitor]] (SRI) |
* [[Serotonin reuptake inhibitor]] (SRI) |
||
* [[Selective_serotonin_reuptake_enhancer|Serotonin reuptake enhancer]] (SRE) |
|||
}} |
}} |
||
| group2 = [[Amino acid|AA]] |
| group2 = [[Amino acid|AA]] |
||
| list2 = {{Navbox |
| list2 = {{Navbox|subgroup |
||
| group6 = [[ |
| group6 = [[GABAergic]] |
||
| list6 = |
| list6 = |
||
* [[GABA agonist|GABA receptor agonist]] |
* [[GABA agonist|GABA receptor agonist]] |
||
| Line 87: | Line 83: | ||
* [[GABA reuptake inhibitor]] (GRI) |
* [[GABA reuptake inhibitor]] (GRI) |
||
| group7 = [[ |
| group7 = [[Glutamatergic]] |
||
| list7 = |
| list7 = |
||
* [[Excitatory amino acid agonist|Glutamate receptor agonist]] ([[Ampakine|AMPA]]) |
* [[Excitatory amino acid agonist|Glutamate receptor agonist]] ([[Ampakine|AMPA]]) |
||
* [[Excitatory amino acid antagonist|Glutamate receptor antagonist]] ([[NMDA receptor antagonist|NMDA]]) |
* [[Excitatory amino acid antagonist|Glutamate receptor antagonist]] ([[NMDA receptor antagonist|NMDA]]) |
||
* [[Excitatory amino acid reuptake inhibitor|Glutamate reuptake inhibitor]] |
|||
| ⚫ | |||
}} |
|||
| group3 = [[Cholinergic]] |
| group3 = [[Cholinergic]] |
||
| Line 99: | Line 95: | ||
* [[Parasympathomimetic_drug|Acetylcholine receptor agonist]] ([[Muscarinic agonist|Muscarinic]] |
* [[Parasympathomimetic_drug|Acetylcholine receptor agonist]] ([[Muscarinic agonist|Muscarinic]] |
||
* [[Nicotinic agonist|Nicotinic]]) |
* [[Nicotinic agonist|Nicotinic]]) |
||
**[[Cholinesterase inhibitor]] |
|||
* [[Anticholinergic|Acetylcholine receptor antagonist]] ([[Muscarinic antagonist|Muscarinic]] |
* [[Anticholinergic|Acetylcholine receptor antagonist]] ([[Muscarinic antagonist|Muscarinic]] |
||
* [[Nicotinic antagonist|Nicotinic]] ([[Ganglionic blocker|Ganglionic]] |
* [[Nicotinic antagonist|Nicotinic]] ([[Ganglionic blocker|Ganglionic]] |
||
* [[Neuromuscular-blocking drug|Muscular]])) |
* [[Neuromuscular-blocking drug|Muscular]])) |
||
| ⚫ | |||
| ⚫ | |||
| list4 = |
| list4 = |
||
* [[Cannabinoid|Cannabinoid receptor agonist]] |
* [[Cannabinoid|Cannabinoid receptor agonist]] |
||
* [[Cannabinoid receptor antagonist]] |
* [[Cannabinoid receptor antagonist]] |
||
* [[Endocannabinoid enhancer]] (eCBE) |
|||
* [[Endocannabinoid reuptake inhibitor]] (eCBRI) |
|||
| group8 = [[ |
| group8 = [[Opioidergic]] |
||
| list8 = |
| list8 = |
||
* [[Opioid modulator]] |
|||
* [[Opioid|Opioid receptor agonist]] |
* [[Opioid|Opioid receptor agonist]] |
||
* [[ |
* [[Opioid antagonist|Opioid receptor antagonist]] |
||
* [[Enkephalinase inhibitor]] |
|||
| group10 = Other |
| group10 = Other |
||
| Line 132: | Line 131: | ||
}} |
}} |
||
| ⚫ | |||
| ⚫ | |||
{{Documentation|content= |
|||
| ⚫ | |||
{{ |
{{Collapsible option}} |
||
[[Category:Drug navigational boxes]] |
|||
[[Category:Pharmacology templates]] |
|||
</noinclude> |
}}</noinclude> |
||
Latest revision as of 09:52, 23 May 2023
Template documentationThis template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.
To change this template's initial visibility, the |state= parameter may be used:
{{Pharmacomodulation|state=collapsed}}will show the template collapsed, i.e. hidden apart from its title bar.{{Pharmacomodulation|state=expanded}}will show the template expanded, i.e. fully visible.